Orbas 20 mg (Tablet)

Therapeutic Class

• Angiotensin II receptor blocker

Indications

• Treatment of hypertension
• Can be used alone or in combination with other antihypertensive agents

Pharmacology

• Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor in vascular smooth muscle
• Has more than a 12,500-fold greater affinity for the AT 1 receptor than for the AT 2 receptor
• Does not inhibit ACE (kininase II) or affect the response to bradykinin

Dosage & Administration

• Usual recommended starting dose of Olmesartan is 20 mg once daily when used as monotherapy
• For patients requiring further reduction in blood pressure after 2 weeks, the dose may be increased to 40 mg
• No initial dosage adjustment recommended for elderly patients or patients with moderate to marked renal impairment or hepatic dysfunction
• Paediatric use has not been established

Interaction

• No significant drug interactions reported in studies with digoxin or warfarin
• Bioavailability of olmesartan not significantly altered by co-administration of antacids
• Not metabolized by the cytochrome P450 system and has no effects on P450 enzymes

Contraindications

• Contraindicated in patients hypersensitive to any component of the product

Side Effects

• Well tolerated with an incidence of adverse reactions similar to placebo
• The overall frequency of adverse reactions was not dose related
• The only adverse reaction that occurred in more than 1% of patients treated with Olmesartan and at a higher incidence versus placebo was dizziness

Pregnancy & Lactation

• Discontinue use when pregnancy is detected
• Drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus
• Potential adverse effects on nursing infant

Precautions & Warnings

• Changes in renal function may be anticipated in susceptible individuals
• Treatment may be associated with oliguria, progressive azotemia, and acute renal failure

Overdose Effects

• No known experience of overdose with Orbas
• Potential effects of overdosage include hypotension and tachycardia
• Clinically significant hypotension due to overdose requires active support of the cardiovascular system

Storage Conditions

• Store in cool & dry place below 30°C
• Protect from light & moisture
• Keep out of the reach of children

Chemical Structure

• Molecular Formula: C29H30N6O6

Uses

• Used to treat high blood pressure

Peak Effect

• Average time taken to reach peak effect is around 1 day to 1 week

Frequency of Use

• Generally used once or twice a day

Usage Instructions

• Orbas 20 mg Tablet is advised to be consumed orally
• Consult the doctor for appropriate usage instructions

Storage Instructions

• Store at room temperature away from heat and direct light
• Keep away from the reach of children

Administration Time

• Take at the same time every day to help remember to take it

Potential Side Effects

• May cause dizziness for the first few days
• Rise slowly to avoid dizziness if sitting or lying down for a long time

Monitoring

• Doctor may get regular tests done to monitor the level of urea, creatinine, and potassium in the blood

Drug Interactions

• Avoid taking anti-inflammatory medicines such as ibuprofen without consulting the doctor
• May interact with NSAIDs and selective COX-2 inhibitors

Dietary Restrictions

• Avoid potassium supplements and potassium-rich foods such as banana, fruit juice, coconut water, and broccoli

Usage during Pregnancy

• Discontinue if pregnancy is detected

Usage during Breastfeeding

• Consider potential adverse effects on nursing infant

Cessation of Use

• Do not stop taking it suddenly without talking to the doctor

Related Brands

• Orbas 40 mg (Tablet) - acme-laboratories-ltd
• Olme 20 mg (Tablet) - albion-laboratories-limited
• Olme 40 mg (Tablet) - albion-laboratories-limited
• Olme 10 mg (Tablet) - albion-laboratories-limited
• Presulock 20 mg (Tablet) - aristopharma-ltd